Prihlásiť sa Zaregistrujte sa zadarmo

Last updated: 23 June 2023 at 4:48pm EST

Ann Barbier Net Worth



Ann Barbier biography

Dr. Ann Barbier M.D. Ph.D. serves as Independent Director of the Company. Dr. Barbier joined the Board of Directors of Pieris in April 2018. She is currently the Chief Medical Officer of Translate Bio. Prior to joining Translate Bio, from June 2015 to October 2017, Dr. Barbier was Vice President of Clinical Development, Rare Genetic Diseases, at Agios Pharmaceuticals, where she led the development program of a small molecule in rare benign hematological diseases. Prior to Agios Pharmaceuticals, Dr. Barbier spent seven years at Shire, most recently as Global Clinical Development Lead and Senior Medical Director, where she worked on a variety of rare genetic diseases including lysosomal storage diseases and hereditary angioedema. Her prior experience includes positions at Envivo, Johnson & Johnson and Aventis. During her career, Dr. Barbier has made significant contributions to several approved products such as idursulfase (Hunter syndrome), teriflunomide (multiple sclerosis) and icatibant (hereditary angioedema), and has led several investigational new drug applications for new chemical entities. Additionally, she has authored more than 50 peer-reviewed scientific articles, book chapters, and invited reviews. Dr. Barbier received her M.D. and Ph.D. in pharmacology from the University of Gent, Belgium, and a Master of Science from the Free University of Brussels, Belgium. She pursued a postdoctoral fellowship at the University of Tennessee in Memphis. Barbier is qualified to serve on our Board of Directors due to her significant experience of bringing drug candidates across a wide range of indications through the clinic and to regulatory approval.

What is the salary of Ann Barbier?

As the Independent Director of Pieris Pharmaceuticals Inc, the total compensation of Ann Barbier at Pieris Pharmaceuticals Inc is $81,321. There are 12 executives at Pieris Pharmaceuticals Inc getting paid more, with Stephen Yoder having the highest compensation of $1,593,600.



How old is Ann Barbier?

Ann Barbier is 56, he's been the Independent Director of Pieris Pharmaceuticals Inc since 2018. There are 4 older and 13 younger executives at Pieris Pharmaceuticals Inc. The oldest executive at Pieris Pharmaceuticals Inc is Peter Kiener, 68, who is the Independent Director.

What's Ann Barbier's mailing address?

Ann's mailing address filed with the SEC is C/O PIERIS PHARMACEUTICALS, INC., 225 FRANKLIN STREET, 26TH FLOOR, BOSTON, MA, 02110.

Insiders trading at Pieris Pharmaceuticals Inc

Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit... a Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.



What does Pieris Pharmaceuticals Inc do?

pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche



What does Pieris Pharmaceuticals Inc's logo look like?

Pieris Pharmaceuticals Inc logo

Pieris Pharmaceuticals Inc executives and stock owners

Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include: